Adipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 and Erk1/2
© Przybyt et al; licensee BioMed Central Ltd. 2013
Received: 29 January 2013
Accepted: 5 February 2013
Published: 13 February 2013
Experimental clinical stem cell therapy has been used for more than a decade to alleviate the adverse aftermath of acute myocardial infarction (aMI). The post-infarcted myocardial microenvironment is characterized by cardiomyocyte death, caused by ischemia and inflammation. These conditions may negatively affect administered stem cells. As postnatal cardiomyocytes have a poor proliferation rate, while induction of proliferation seems even more rare. Thus stimulation of their proliferation rate is essential after aMI. In metaplastic disease, the pro-inflammatory cytokine interleukin-6 (IL-6) has been identified as potent mediators of the proliferation rate. We hypothesized that IL-6 could augment the proliferation rate of (slow-)dividing cardiomyocytes.
To mimic the behavior of therapeutic cells in the post-infarct cardiac microenvironment, human Adipose Derived Stromal Cells (ADSC) were cultured under hypoxic (2% O2) and pro-inflammatory conditions (IL-1β) for 24h. Serum-free conditioned medium from ADSC primed with hypoxia and/or IL-1β was added to rat neonatal cardiomyocytes and adult cardiomyocytes (HL-1) to assess paracrine-driven changes in cardiomyocyte proliferation rate and induction of myogenic signaling pathways.
We demonstrate that ADSC enhance the proliferation rate of rat neonatal cardiomyocytes and adult HL-1 cardiomyocytes in a paracrine fashion. ADSC under hypoxia and inflammation in vitro had increased the interleukin-6 (IL-6) gene and protein expression. Similar to conditioned medium of ADSC, treatment of rat neonatal cardiomyocytes and HL-1 with recombinant IL-6 alone also stimulated their proliferation rate. This was corroborated by a strong decrease of cardiomyocyte proliferation after addition of IL-6 neutralizing antibody to conditioned medium of ADSC. The stimulatory effect of ADSC conditioned media or IL-6 was accomplished through activation of both Janus Kinase-Signal Transducer and Activator of Transcription (JAK/STAT) and Mitogen-Activated Protein (MAP) kinases (MAPK) mitogenic signaling pathways.
ADSC are promising therapeutic cells for cardiac stem cell therapy. The inflammatory and hypoxic host post-MI microenvironment enhances the regenerative potential of ADSC to promote the proliferation rate of cardiomyocytes. This was achieved in paracrine manner, which warrants the development of ADSC conditioned medium as an “of-the-shelf” product for treatment of post-myocardial infarction complications.
Postnatal cardiomyocytes (CM) have a limited proliferation rate that does not suffice to replenish the CM that are massively lost after Myocardial Infarction (MI). During human life span approximately half of the cardiomyocytes are replaced [1, 2]. This indicates that there is a significant level of physiological proliferation of cardiomyocytes. Thus, novel therapies that promote the proliferation of CM after acute Myocardial Infarction (aMI) may alleviate post-infarct complications such as heart failure.
Over the past decade, mesenchymal stem cells (MSC) emerged as promising candidates for cardiac therapy. Stem cells and progenitor cells from sources that vary from bone marrow to adipose tissue and the heart itself have shown to be beneficial in animal models of aMI and in clinical trials [3–5]. The current dogma is that stem cells act primarily through paracrine intervention in the damaged cardiac microenvironment i.e. through secretion of trophic factors [6, 7]. The secretion profile and the fate of administrated cells change upon a host microenvironment. Current research on preconditioning BM-MSC with the hypoxic and the inflammatory factors found in post-MI microenvironment improve the cardioprotective outcome of the therapeutic cells [8–10]. Thus priming Adipose tissue-derived stem cells (ADSC) for the treatment of MI with hypoxic and inflammatory conditions might result in the improvement of cardiac function.
ADSC belong to the family of MSC and are derived from the adipose vascular stromal fraction as fibroblastic, spindle-shaped, plastic adherent cells and co-express several mesenchymal markers such as CD105, CD90, CD44, CD29 or CD73 [11, 12]. In vitro, ADSC secrete a plethora of factors that are cytoprotective, promote angiogenesis and induce proliferation of various cell types [13–15]. Indeed, in animal models of myocardial infarction, the intramyocardial administration of ADSC improved cardiac remodeling and function [16, 17]. Yet, the influence of administered stem cells on the proliferation rate of cardiomyocytes is poorly studied.
In damaged tissues, interleukin-6 (IL-6) is both cytoprotective and anti-apoptotic [18, 19]. However, during the late post-MI healing phase IL-6 is upregulated in the myocardium. This chronic exposure to IL-6 activates as a compensatory hypertrophic reaction of the surrounding cardiac tissue and may contribute to cardiac fibrosis. IL-6 acts as a mitogen on several cell types, e.g. on hepatocytes during liver regeneration. Furthermore, IL-6 facilitates healing of damaged skeletal muscle through mitotic stimulation of muscle progenitor cells [20, 21]. IL-6 binds to the IL-6/gp130 receptor complex and activates the associated Janus Kinase (JAK), which phosphorylates, i.e. activates STAT3 (signal transduction and activator of transcription) to p-STAT3. The p-STAT3 translocates to the nucleus and initiates transcription of its responsive genes. STAT3 activation can also occur through cross-talk between other mitogenic signaling pathways, such as the mitogen activated protein kinase (MAPK) pathway . One of the trophic factors readily secreted by ADSC is IL-6. Therefore, we hypothesized that IL-6 secreted by ADSC could stimulate the rate of cardiomyocyte proliferation through JAK/STAT and MAPK-dependent pathways.
Materials and methods
ADSC isolation and culture
Human subcutaneous adipose tissue samples were obtained after liposuction surgery, which was donated upon informed consent of the healthy patients with BMI below 30 (Bergman Clinics, The Netherlands). Adipose tissue was stored at 4°C and processed within 24 h post surgery. Following extensive washing with PBS, the tissue was enzymatically digested with 0.1% Collagenase A, (Roche Diagnostic, Mannheim, Germany) 1:1 in PBS, containing 1% bovine serum albumine (BSA; Sigma-Aldrich, Boston, MA) at 37°C for 1 h. Digested tissue was washed with PBS, 1% BSA to remove the adipocytes and lipid content. The cell pellet was resuspended in PBS, 1% BSA and subjected to Lymphoprep (Axis-Shield PoC, Oslo, Norway) density gradient centrifugation. The cells from the interface were collected and washed with PBS, 1% BSA and resuspended in DMEM (Lonza Biowhittaker, Verviers, Belgium), 10% FBS (Thermo Scientific, Hemel Hempstead, UK), 100 U/mL penicillin, 100 mg/mL streptomycin (Gibco, Invitrogen, Carlsbad, CA) and 2 mM L-glutamine (Lonza Biowhittaker, Verviers, Belgium). Cells were seeded in culture flasks at 4x104/cm2, expanded till Passage 3 and used for experiments. The use of liposuction material as source of ADSC was approved by of the local Ethics Committee of University Medical Centre Groningen, given the fact that it was considered the use of anonymised waste material. Yet, for every one of these anonymous donations the clients gave their consent after information.
Cardiomyocytes isolation and culture
Rat neonatal cardiac tissues were collected and kept in a head-over-head rotator at 4°C in trypsin (Gibco, Invitrogen, Carlsbad, CA) overnight. Afterwards, the tissues were enzymatically digested with 550 U of Collagenase A, (Roche Diagnostic, Mannheim, Germany) and filtered through 70 μm cell straine into the cold FCS solution (Gibco, Invitrogen, Carlsbad, CA). The cell suspension was resuspended in DMEM (Lonza Biowhittaker, Verviers, Belgium), 10% FCS (Gibco, Invitrogen, Carlsbad, CA), 100 U/mL penicillin, 100 mg/mL streptomycin (Gibco, Invitrogen, Carlsbad, CA) and 2 mM L-glutamine (Lonza Biowhittaker, Verviers, Belgium). Fibroblasts were depleted through plastic adhesion, non-adhered cells i.e. cardiomyocytes were re-seeded at 20,000 cells/cm2 in fibronectin-coated flasks (25 μg/ml , Harbor Bio-products, Noordwood, MA). Animal experiments, i.e. the use of neonatal rat heart for the isolation of cardiomyocytes was approved by the local committee for animal experiments of the Amsterdam University Medical Centre. Animal experimentation was approved by the local committee for care and use of laboratory animals and performed according to strict governmental and international guidelines. The investigation conformed to Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
HL-1 murine cardiomyocytes were a kind gift of Dr. William C. Claycomb (Department of Biochemistry and Molecular Biology, Louisiana State University Health Science Center, New Orleans, LA, USA). Cells were maintained in fibronectin-coated flasks in Claycomb expansion medium (Sigma-Aldrich, Boston, MA,) supplemented with 10% FBS (Sigma-Aldrich, Boston, MA), 0.1 mM norepinephrine (Sigma-Aldrich, Boston, MA), 100 U/mL penicillin, 100 mg/mL streptomycin (Gibco, Invitrogen, Grand Island, NY) and 2mM L-glutamine (Lonza Biowhittaker, Verviers, Belgium) and kept semi-confluent at all times.
Experimental culture conditions
Prior to co-cultures of ADSC and rat neonatal cardiomyocytes (rnCM) the cells were labeled with the CFDA SE (green) and CM-DiI (red) respectively according to the manufacturer’s instructions (both Molecular probes, Invitrogen, Grand Island, NY). Co-cultures of ADSC and HL-1 cardiomyocytes were done after lentivirus tagging with resp. lentiviruses encoding eGFP and dTomato. Briefly, on the day of transduction, cells were plated at 1× 106 cells/well in serum-free growth medium containing 5 μg/ml polybrene (Sigma-Aldrich, Boston, MA). Following overnight incubation, medium was replaced with normal growth medium containing 10% FBS. The medium of HL-1 cells was changed once per 24h while ADSC medium was replenished three times a week. At five days post-transduction, cells were FACS sorted based on expression of eGFP or dTOMATO to obtain pure cell population. To determine the influence of the ADSC density on cardiomyocyte proliferation, ADSC were treated with 10 μg/ml mitomycin-C (Sigma-Aldrich, Boston, MA) for 3h, followed by extensive washing with PBS prior the co-culture with rnCM and HL-1 cells. The ADSC cell ratios plated in co-culture conditions varied from 1:1 to 1:3 for rnCM, while keeping the rnCM at 20,000 cells/cm2. The ADSC ratios in co-cultures with HL-1 cells varied from 1:1 to 1:4, while keeping the HL-1 cells at 6,000 cells/cm2. Simultaneously, cells were labeled with 1 μM BrdUrd-bromodeoxyuridine (Sigma-Aldrich, Boston, MA) for 6h at the end of the experiment. In order to study the effect of the post-MI microenvironment on cardiomyocytes, rnCM and HL-1 cells and ADSC were cultured at ambient oxygen tension 21% O2 (normoxia) or at 2% O2, (hypoxia). At these oxygen tensions inflammation was mimicked by continuous treatment with TNF-α or IL-1β (both 10 ng/ml Peprotech, Rocky Hill, NJ) or none as a control for 24 and 48h respectively. ADSC conditioned medium was collected after pre-treatment according to the experimental procedures for 24h. Subsequently, followed by medium replacement without the stimuli and conditioning in 0% FBS Claycomb Medium for 24h.
Gene transcript analysis
Primer sequence for qRT-PCR
ADSC conditioned medium was collected and filtered through 0.2 μm filter to remove any residual debris. To quantify the IL-6 production by ADSC, collected media were assessed by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) according to manufacturer’s protocol. Absorbance values for individual reactions were determined using VersaMax™ Microplate Reader with SoftmaxPro 3.0 data processing software. To assure statistically relevant data, samples were run in triplicate from three independent donors.
Confluent rnCM or HL-1 cardiomyocyte cultures were serum-starved overnight. Subsequently, 50 μM Stattic (STAT3 inhibitor) (Calbiochem, Darmstadt, Germany) or 10 μM UO126 (MEK-1 inhibitor) (Promega, Madison, WI) and solvent controls were added to HL-1 cells for 2h. Next, rnCM or HL-1 cultures were treated with ADSC conditioned medium for 30min. Protein lysates from serum depleted, confluent cultures of HL- 1 cells were prepared in RIPA buffer (Thermo Scientific, Rockford, IL,) supplemented with 1% protease inhibitor cocktail and 1% phosphatase inhibitors cocktail 2, 3 (Sigma-Aldrich, Boston, MA). Cell lysates (20 μg) were run on 10% polyacrylamide electrophoresis gel and blotted onto nitrocellulose membrane according to standard protocol. Blots were blocked in Tris-buffered saline (TBS) containing 5% BSA (Sigma-Aldrich, Boston, MA) for 1 h. Subsequently, blots were incubated in TBS-1% Tween containing 5% BSA with primary antibodies to human p-STAT3 (Y705), STAT3 (Cell Signaling Technology, Beverly, MA), p-Erk1/2 (Thr 202/Tyr 204), Erk1/2 (42/44) (Cell Signaling Technology, Beverly, MA), diluted 1:1000, overnight. Afterwards, blots were washed and incubated with alkaline phosphatase-conjugated antibodies to mouse or rabbit IgG, at the dilution 1:2000 for 1 h. NBT/BCIP (Bio-Rad, VA) was used as a substrate for detection. Densitometric analysis was performed using Totallab 120 (Nonlinear Dynamic, Newcastle upon Tyne, England).
Immunofluorescence microscopy and image analysis
rnCM and HL-1 cardiomyocytes were seeded semi-confluent onto polystyrene 8-chamber slides (Thermo Scientific, Hemel Hempstead, UK). Subsequently, cells were serum-starved in serum-free Claycomb Medium overnight. Afterwards, samples were stimulated with 10 ng/ml IL-6 (Peprotech, Rocky Hill, NJ), conditioned media of ADSC and conditioned media of ADSC supplemented with IL-6 neutralizing antibody (1.2 μg/ml) or Mock IgG (5.33 μg/ml) as a control (all R&D Systems, Minneapolis, MN) for 24 h. As a growth control, 10% FBS Claycomb Medium was used. Simultaneously, cells were labeled with 1 μM BrdUrd (Sigma-Aldrich, Boston, MA) for last 6h. Next, cells were fixed using 2% paraformaldehyde at room temperature for 20 min. After extensive washing, cells were permeabilized with 0.5% Triton X-100 in PBS (Sigma-Aldrich, MA). Samples were treated with 0.7 M HCl and 0.05% pepsin at 37°C and post-fixed with paraformaldehyde (4% in PBS). Subsequently, samples were incubated with primary antibody sheep polyclonal biotinylated α-BrdUrd (Abcam, Cambridge, UK) diluted 1:100 in PBS with 10% goat serum (First Link Ltd, UK) overnight. Samples were washed extensively and incubated with secondary antibody Streptavidin-FITC for HL-1 cells and Streptavidin-Cy 3 for rnCM (Dako, Carpinteria, CA) diluted 1:400 in 3 μM DAPI in PBS with 10% mouse serum (Sanquin, Amsterdam, The Netherlands) for 30 minutes.
To determinate the working mechanism of cardiomyocyte proliferation, serum-free cultured HL-1 cardiomyocytes were cultured in the presence of 50 μM JAK1 inhibitor (AG490) or 50 μM STAT3 inhibitor (Stattic) (Calbiochem, Darmstadt, Germany), 10 μM RAS inhibitor (FTS) (Cayman Chemical Co., Ann Arbor, MI) or 10 μM MEK inhibitor (U0126) (Promega, Madison, WI) and according controls with DMSO for 2h. Afterwards, cells were extensively washed with PBS and cultured in 5% Claycomb medium or ADSC conditioned medium in the presence of 1μM BrdUrd for 6 h. Next, samples were fixed using 2% paraformaldehyde and proceed with BrdUrd staining as mentioned above. Stained samples were extensively washed and proceed with Tissue FAXS analysis to quantify percentage of BrdUrd positive HL-1 cardiomyocytes. Examination was performed by immunofluorescent microscopy using a Leica DMRXA microscope and Leica software (Leica Microsystems), and further quantification was performed by TissueFAXS using a Zeiss AxioObserver. Z1 microscope and TissueQuest cell analysis software (TissueGnostics).
All the data are presented as a means +/− SEM and were analysed by GraphPad Prism (version 5, GraphPad Software Inc.). Statistical significance was determined using one-way ANOVA with Bonferroni post hoc analysis. Values of p < 0.05 were considered statistically significant.
ADSC promote the rate of cardiomyocyte proliferation in direct co-culture
As preparations of neonatal cardiomyocytes comprise are heterogeneous, we also assessed our findings with rnCM in the murine cardiomyocyte cell line HL-1. The proliferation rate of HL-1 cardiomyocytes was dramatically reduced by serum starvation and served to assess changes in the rate of proliferation by ADSC. HL-1 cardiomyocytes were co-cultured with ADSC in ratios 1:1 to 1:4. ADSC were pre-treated with mitomycin-C to induce cell cycle arrest. This allowed for the quantification of BrdUrd incorporation in actively proliferating HL-1 cardiomyocytes. ADSC significantly enhanced the rate of proliferation of HL-1 cardiomyocytes by 45% and 46% in 1:1 and 1:3 ratios compared to HL-1 cardiomyocyte alone (p < 0.05, Figure 1C, H). To investigate if various ratios of ADSC influence cardiomyocyte density, lentivirally eGFP-tagged ADSC (green) were co-cultured with lentivirally dTomato-tagged HL-1 cardiomyocytes (red). The HL-1 cell density doubled in a 1:1 and 1:2 ratio and further increased in a 1:3 and 1:4 ratio compared to HL-1 cardiomyocytes alone (p < 0.05, Figure 1B, D). ADSC enhanced HL-1 cardiomyocyte proliferation rate in all ratios, no significant differences were found between various ratios of ADSC to HL-1 cardiomyocytes (p < 0.05, Figure 1E, I).
Conditioned medium of ADSC promotes the rate of proliferation of HL-1 cardiomyocytes
In normal culture medium, approximately 85% of the HL-1 cardiomyocytes proliferated under both normoxic and hypoxic conditions. Serum starvation reduced the fraction of proliferating HL-1 cardiomyocytes almost two fold under normoxia or hypoxia. Treatment of serum-free HL-1 cardiomyocytes with TNF-α or IL-1β did not alter proliferation, irrespective of oxygen concentration. Serum-free-conditioned medium from normoxically cultured ADSC increased the proliferation rate of serum-free HL-1 cardiomyocytes by 18% compared to serum-free HL-1 cardiomyocytes control (p < 0.05). The proliferation rate of HL-1 cardiomyocytes under normoxic conditions was even further stimulated (35%, p < 0.05) upon incubation with conditioned medium from ADSC prestimulated with TNF-α or IL-1β compared to TNF-α or IL-1β stimulated serum-free HL-1 cardiomyocytes controls. The pro-inflammatory stimulation of ADSC with TNF-α or IL-1β to obtain primed ADSC conditioned medium ameliorated the cardiomyocyte proliferation rate as well. Furthermore, IL-1β primed conditioned medium of ADSC significantly increased (12%, p < 0.05) the HL-1 proliferation rate compared to nonstimulated conditioned medium of ADSC. Moreover, conditioned medium from hypoxia cultured ADSC ameliorated the proliferation rate of cardiomyocytes even further in comparison to conditioned medium of normoxia cultured ADSC (31% vs. 18% increase, p < 0.05). In addition, conditioned medium of hypoxia cultured ADSC in the presence of pre-stimulation with TNF-α or IL-1β showed only marginally improvement resulting in 40% increase in HL-1 cardiomyocyte proliferation rate (p < 0.05).
Hypoxia and pro-inflammatory mediators upregulate IL-6 secretion by ADSC
Under hypoxia, treatment of ADSC with IL-1β for 24 h and 48 h resulted in higher increase of IL-6 gene expression, respectively by 95-fold and 45-fold ( p < 0.05, Figure 3B).
The level of secreted IL-6 showed a similar pattern as the gene expression after stimulation of ADSC with IL-1β (Figure 3C, D). Stimulation of ADSC with IL-1β , induced a 500-fold increase in IL-6 protein secretion within 24 h, which decreased to approximately 200-fold at 48 h both under normoxia and hypoxia (p < 0.05, Figure 3C, D).
IL-6 secreted by ADSC enhances the cardiomyocyte proliferation rate
Stimulation with IL-6, increased the number of proliferating rnCM from 8% (serum free controls) to 9% (p < 0.05, Figure 3E). Addition of IL-6 neutralizing antibody to the IL-6 treated rnCM reduced the number of proliferating cells to 7% compared to IL-6 treated controls (p < 0.05, Figure 3E). Stimulation of rnCM with the serum free ADSC conditioned medium resulted in increase of proliferating rnCM to 8.5% compared to serum free controls. Addition of IL-6 neutralizing antibody to the conditioned medium of ADSC resulted in significant decrease of proliferating rnCM to 7.4% (p < 0.05, Figure 3E).
Adult HL-1 cardiomyocytes were cultured in the presence of 10% serum. Under serum-free conditions, IL-6 and the conditioned medium of ADSC induced a 24% and 27% upregulation of the proliferation rate of HL-1 cardiomyocytes respectively, compared to HL-1 serum-free control (p < 0.05, Figure 3F). Addition of IL-6 neutralizing antibodies to the IL-6 treated HL-1 cardiomyocytes reduced their proliferation rate by 42% (p < 0.05, Figure 3E) compared to IL-6 treated controls. Treatment of serum-free conditioned medium of ADSC with IL-6 neutralizing antibodies also reduced the rate of HL-1 cardiomyocyte proliferation rate by 13% compared to conditioned medium of ADSC (p < 0.05, Figure 3F).
Conditioned medium of ADSC increase cell cycle progression gene expression profile in HL-1 cardiomyocytes
Conditioned medium of ADSC increases autocrine IL-6 gene expression in HL-1 cardiomyocytes
ADSC conditioned medium-dependent signaling pathways targeting the increased rate of cardiomyocyte proliferation
ADSC-dependent signaling pathways targeting HL-1 cardiomyocyte proliferation rate
In this study we show that Adipose Derived Stromal Cells (ADSC) enhance the proliferation rate of both primary CM and a CM cell line, in a paracrine manner and in direct co-culture in vitro. One of the main stimulators secreted by ADSC was IL-6. The in vitro hypoxic and pro-inflammatory preconditioning of ADSC i.e. mimicking the post-myocardial infarction microenvironment (ischemia and inflammation), strongly upregulated the IL-6 production by ADSC and further augmented the stimulation of the proliferation of cardiomyocytes. The IL-6 stimulated cardiomyocyte proliferation was accomplished through activation of both Janus Kinase-Signal Transducer and Activator of Transcription (JAK/STAT) and Mitogen-Activated Protein (MAP) kinases (MAPK) mitogenic signaling pathways.
Stimulation of rat neonatal cardiomyocytes or HL-1 cardiomyocytes with conditioned medium of ADSC increased their proliferation rate. To mimic the behavior of therapeutic cells in the post-infarct cardiac microenvironment, we stimulated ADSC with hypoxia and pro-inflammatory mediators, which increased their production of IL-6. Remarkably, Efimenko and co-workers, showed that stimulation of MSC from bone marrow or adipose tissue with high concentrations of TNF-α did not alter their profile of pro-angiogenic mediators, which paradoxes to our finding that pro-inflammatory stimulation augmented regenerative potential of therapeutic cells . The differences may be, that different stimuli (TNF versus IL-1) were used and different readouts, i.e. angiogenesis versus cardiomyocyte proliferation. Furthermore, our data indicate that hypoxia alone, but in particular together with a pro-inflammatory stimulus, augment CM proliferation by ADSC conditioned media too. This indicates that hypoxia can further augment the regenerative potential of ADSC. In contrast to current data, not only hypoxia may exert a beneficial effect on ADSC [15, 23]. We found that inflammation had far stronger effect on the ADSC secretion profile. Although hypoxia itself did not alter IL-6 gene expression levels by ADSC, in combination with inflammatory mediators enhanced regenerative potential of ADSC.
Stimulation of rnCM and adult HL-1 cardiomyocytes with IL-6 resulted in an enhanced level of the cardiomyocyte proliferation rate. Targeting IL-6 with neutralizing antibodies against IL-6 in the presence of IL-6 or conditioned medium of ADSC resulted in decreased rate of cardiomyocyte proliferation. The blocking of IL-6 in ADSC conditioned medium only partially inhibited positive effect of ADSC conditioned medium on cardiomyocyte proliferation rate. This suggests that either conditioned medium of ADSC contains additional only mitogenic factors or that other factors promote rnCM and HL-1 cardiomyocyte proliferation rate synergistically with IL-6.
This is corroborated by our observation that stimulation of HL-1 cardiomyocytes with conditioned medium of ADSC resulted in a significant increase of c-myc and IL-6 receptor complex gp130/gp80, while stimulation with IL-6 alone did not show significance gene expressions changes.
Similarly, previous studies on skeletal muscle have shown that regular exercise causes damage that is followed by increased IL-6 level. The released IL-6 activates the JAK/STAT signaling pathway and augments repair of skeletal muscle . Recent clinical therapies with postconditioning of the ischemic heart show beneficial effect on the reduction of the scar size due to the activation of STAT3  and involvement of IL-6 in this process . In addition, pro-inflammatory cytokines such as TNF-α related TWEAK or ligands from EGF family such as neuregulin and HB-EGF provided evidence for engagement MAPK in induction of the cardiomyocyte proliferation rate [27–29].
Conditioned medium of ADSC activated the downstream JAK1 and JAK2/TYK2 that lead to their target STAT3 Tyr705 phosphorylation in rnCM and HL-1 cardiomyocytes. Blocking of JAK1 with commonly used JAK/STAT inhibitor did not diminished the level of phosphorylated STAT3, suggesting that JAK/STAT activation can also occur through JAK2/TYK2 . Remarkably, direct inhibition of phosphorylated STAT3 with Stattic resulted in reduced STAT3 and increased levels of phosphorylated Erk1/2 (Figure 6). This suggests that the stimulated proliferation rate of HL-1 cardiomyocytes is a balance between STAT3 signaling and MAPkinase signaling . Although prolonged inhibition of one of the upstream or downstream of JAK/STAT or MAPK pathways lead to decreased proliferation rate of HL-1 cardiomyocytes either in the presence of mitogenic factors or conditioned medium of ADSC.
The therapeutic benefit of stem cells for cardiac therapy is well-accepted, however the stem cell response to the host’s post-MI microenvironment is uncertain . The main mode of action of cardiac stem cell therapy is through paracrine mechanisms. Indeed, the intravenous administration of conditioned culture media from bone marrow derived MSC in pigs improved cardiac remodeling and perfusion [33, 34]. To unravel the mechanism of paracrine therapeutic benefit of cardiac stem cell therapy, we subjected cardiomyocytes to the conditioned medium of ADSC.
The post-infarct cardiac microenvironment consists of an imbalanced level of inflammatory and anti-inflammatory mediators that correlate with the outcome of diseased myocardium. Cytokines might exert different function in time and dose dependent manner. Prolonged chronic high levels of IL-6 after MI are considered as a cause of hypertrophy and heart failure. Recent studies demonstrate that pro-inflammatory cytokines can activate cardioprotective signaling pathways in the post-infarct heart. IL-6 though might exert dynamic actions and act as a potent “myokine”, where in a rapid response to acute myocardial infarction it activates cardioprotective pathways , resulting in increase in cardiomyocyte proliferation. Application of the conditioned medium derived from therapeutic cells rather than cells themselves would circumvent the problem of retention in cardiac stem cell therapy. Additionally, the current approach of use of primed conditioned medium of therapeutic stem cells offer “off -the-shelf” product, which may be used for multiple injections.
The authors gratefully acknowledge Anna Rita Bellu, Jojanneke Middeljans, Marije Bakker, Roland van Leeuwen, Klaas Sjollema and the financial support of the Translational Excellence in Regenerative Medicine (TeRM) SmartMix Program of the Netherlands Ministry of Economic Affairs and the Netherlands Ministry of Education, Culture and Science. This research was further supported by the Groningen University Institute Drug Exploration (GUIDE) of the University of Groningen and the University Medical Center Groningen and grants from the J.K. de Cock Foundation and the Netherlands Organisation for Scientific Research (NWO). G.K. is supported by the Netherlands Organization for Scientific Research and the Netherlands Organization for Health Research and Development (NOW/ZonMW #916.11.022). M.C.H. is supported by the Groningen University Institue for Drug Exploration (GUIDE) and the W.J. Kolff Institute for Biomedical Materials Science and Application of the University of Groningen. Microscopical imaging was performed at the UMCG Imaging Center (UMIC), which is supported by the Netherlands Organisation for Health Research and Development (ZonMW grant 40-00506-98-9021).
- Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J: Evidence for cardiomyocyte renewal in humans. Science. 2009, 324: 98-102. 10.1126/science.1164680.PubMed CentralView ArticlePubMedGoogle Scholar
- Kajstura J, Rota M, Cappetta D, Ogorek B, Arranto C, Bai Y, Ferreira-Martins J, Signore S, Sanada F, Matsuda A, Kostyla J, Caballero MV, Fiorini C, D’Alessandro DA, Michler RE, Del Monte F, Hosoda T, Perrella MA, Leri A, Buchholz BA, Loscalzo J, Anversa P: Cardiomyogenesis in the aging and failing human heart. Circulation. 2012, 126: 1869-1881. 10.1161/CIRCULATIONAHA.112.118380.PubMed CentralView ArticlePubMedGoogle Scholar
- Braun T, Dimmeler S: Breaking the silence: stimulating proliferation of adult cardiomyocytes. Dev Cell. 2009, 17: 151-153. 10.1016/j.devcel.2009.07.022.View ArticlePubMedGoogle Scholar
- Angert D, Berretta RM, Kubo H, Zhang H, Chen X, Wang W, Ogorek B, Barbe M, Houser SR: Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ Res. 2011, 108: 1226-1237. 10.1161/CIRCRESAHA.110.239046.PubMed CentralView ArticlePubMedGoogle Scholar
- Miettinen JA, Ylitalo KV, Niemela M, Kervinen K, Saily M, Koistinen P, Savolainen ER, Makikallio TH, Huikuri HV: Left ventricular functional recovery after intracoronary injection of autologous bone marrow-derived stem cells in patients with acute myocardial infarction: a dose–response pilot study. Int J Cardiol. 2011, 154: 354-356.View ArticlePubMedGoogle Scholar
- Hwang H, Kloner RA: Improving regenerating potential of the heart after myocardial infarction: factor-based approach. Life Sci. 2010, 86: 461-472. 10.1016/j.lfs.2010.01.004.View ArticlePubMedGoogle Scholar
- Willems E, Lanier M, Forte E, Lo F, Cashman J, Mercola M: A chemical biology approach to myocardial regeneration. J Cardiovasc Transl Res. 2011, 4: 340-350. 10.1007/s12265-011-9270-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR: Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2010, 33: 24-30. 10.1097/SHK.0b013e3181b7d137.View ArticlePubMedGoogle Scholar
- Herrmann JL, Weil BR, Abarbanell AM, Wang Y, Poynter JA, Manukyan MC, Meldrum DR: IL-6 and TGF-alpha costimulate mesenchymal stem cell vascular endothelial growth factor production by ERK-, JNK-, and PI3K-mediated mechanisms. Shock. 2011, 35: 512-516. 10.1097/SHK.0b013e31820b2fb9.View ArticlePubMedGoogle Scholar
- Luo Y, Wang Y, Poynter JA, Manukyan MC, Herrmann JL, Abarbanell AM, Weil BR, Meldrum DR: Pretreating mesenchymal stem cells with interleukin-1beta and transforming growth factor-beta synergistically increases vascular endothelial growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia. Surgery. 2011, 151: 353-363.View ArticlePubMedGoogle Scholar
- Atsma DE, Fibbe WE, Rabelink TJ: Opportunities and challenges for mesenchymal stem cell-mediated heart repair. Curr Opin Lipidol. 2007, 18: 645-649. 10.1097/MOL.0b013e3282f0dd1f.View ArticlePubMedGoogle Scholar
- Daher SR, Johnstone BH, Phinney DG, March KL: Adipose stromal/stem cells: basic and translational advances: the IFATS collection. Stem Cells. 2008, 26: 2664-2665. 10.1634/stemcells.2008-0927.View ArticlePubMedGoogle Scholar
- Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM: Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol. 2007, 212: 702-709. 10.1002/jcp.21068.View ArticlePubMedGoogle Scholar
- Efimenko AI, Starostina EE, Rubina KA, Kalinina NI, Parfenova EV: Viability and angiogenic activity of mesenchymal stromal cells from adipose tissue and bone marrow in hypoxia and inflammation in vitro. Tsitologiia. 2010, 52: 144-154.PubMedGoogle Scholar
- Efimenko A, Starostina E, Kalinina N, Stolzing A: Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J Transl Med. 2011, 9: 10-10.1186/1479-5876-9-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang DZ, Gai LY, Liu HW, Jin QH, Huang JH, Zhu XY: Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction. Chin Med J (Engl). 2007, 120: 300-307.Google Scholar
- Yu LH, Kim MH, Park TH, Cha KS, Kim YD, Quan ML, Rho MS, Seo SY, Jung JS: Improvement of cardiac function and remodeling by transplanting adipose tissue-derived stromal cells into a mouse model of acute myocardial infarction. Int J Cardiol. 2010, 139: 166-172. 10.1016/j.ijcard.2008.10.024.View ArticlePubMedGoogle Scholar
- Matsushita K, Iwanaga S, Oda T, Kimura K, Shimada M, Sano M, Umezawa A, Hata J, Ogawa S: Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest. 2005, 85: 1210-1223. 10.1038/labinvest.3700322.View ArticlePubMedGoogle Scholar
- Waxman AB, Kolliputi N: IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins. Am J Respir Cell Mol Biol. 2009, 41: 385-396. 10.1165/rcmb.2008-0302OC.PubMed CentralView ArticlePubMedGoogle Scholar
- Wuestefeld T, Klein C, Streetz KL, Betz U, Lauber J, Buer J, Manns MP, Muller W, Trautwein C: Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem. 2003, 278: 11281-11288. 10.1074/jbc.M208470200.View ArticlePubMedGoogle Scholar
- Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH: Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology. 2003, 38: 674-682.View ArticlePubMedGoogle Scholar
- German CL, Sauer BM, Howe CL: The STAT3 beacon: IL-6 recurrently activates STAT 3 from endosomal structures. Exp Cell Res. 2011, 317: 1955-1969. 10.1016/j.yexcr.2011.05.009.PubMed CentralView ArticlePubMedGoogle Scholar
- Thangarajah H, Vial IN, Chang E, El-Ftesi S, Januszyk M, Chang EI, Paterno J, Neofytou E, Longaker MT, Gurtner GC: IFATS collection: Adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. Stem Cells. 2009, 27: 266-274. 10.1634/stemcells.2008-0276.View ArticlePubMedGoogle Scholar
- McKay BR, De Lisio M, Johnston AP, O’Reilly CE, Phillips SM, Tarnopolsky MA, Parise G: Association of interleukin-6 signalling with the muscle stem cell response following muscle-lengthening contractions in humans. PLoS One. 2009, 4: e6027-10.1371/journal.pone.0006027.PubMed CentralView ArticlePubMedGoogle Scholar
- You L, Li L, Xu Q, Ren J, Zhang F: Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and JAK-STAT signaling pathway. Mol Biol Rep. 2011, 38: 437-443. 10.1007/s11033-010-0126-y.View ArticlePubMedGoogle Scholar
- Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R: IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004, 64: 61-71. 10.1016/j.cardiores.2004.05.011.PubMed CentralView ArticlePubMedGoogle Scholar
- Bersell K, Arab S, Haring B, Kuhn B: Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009, 138: 257-270. 10.1016/j.cell.2009.04.060.View ArticlePubMedGoogle Scholar
- Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, Shaw RM, Srivastava D: Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell. 2009, 16: 233-244. 10.1016/j.devcel.2008.12.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, Engel FB: TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res. 2010, 85: 681-690. 10.1093/cvr/cvp360.View ArticlePubMedGoogle Scholar
- Firmbach-Kraft I, Byers M, Shows T, Dalla-Favera R, Krolewski JJ: Tyk2, Prototype of a novel class of Non-receptor tyrosine kinase genes. Oncogene. 1990, 5: 1329-1336.PubMedGoogle Scholar
- Fischer P, Hilfiker-Kleiner D: Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol. 2007, 102: 279-297. 10.1007/s00395-007-0658-z.View ArticlePubMedGoogle Scholar
- Moonen JR, Harmsen MC, Krenning G: Cellular plasticity: the good, the bad, and the ugly? Microenvironmental influences on progenitor cell therapy. Can J Physiol Pharmacol. 2012, 90: 275-285. 10.1139/y11-107.View ArticlePubMedGoogle Scholar
- Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP: Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2007, 1: 129-137.View ArticlePubMedGoogle Scholar
- Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA, Goumans MJ, Strijder C, Sze SK, Choo A, Piek JJ, Doevendans PA, Pasterkamp G, de Kleijn DP: Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res. 2011, 6: 206-214. 10.1016/j.scr.2011.01.001.View ArticlePubMedGoogle Scholar
- Lecour S, James RW: When are pro-inflammatory cytokines SAFE in heart failure?. Eur Heart J. 2011, 32: 680-685. 10.1093/eurheartj/ehq484.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.